INTRODUCTION

Polycystic ovary syndrome (PCOS), is a complex endocrine disorder, characterized by hyperandrogenism, anovulation and polycystic ovary morphology [1]. The prevalence of the disease is estimated to be 5-10% in women of reproductive age [2]. Also, it has been established that there are ethnic and racial variations in the prevalence of PCOS and its symptoms [3]. It is the leading cause of anovulatory infertility and hirsutismus [4]. In addition, women with PCOS are susceptible to obesity, insulin resistance, hypertension, and dyslipidemia that lead to cardiovascular diseases [5]. The pathogenesis of PCOS still remains unclear. However, environment and genetic background are considered to be the potential causative factors for the disease. Twin and familial studies revealed that PCOS is closely associated with genetic factors (6). Recently, it has been shown that there are multiple susceptibility genes encoding sex hormones or regulators of their activities, associated with PCOS [7,8].

Follicle-stimulating hormone (FSH), a secretion of pituitary gland, plays a crucial role in the follicle development, oocyte maturation and steroidogenesis regulation [9]. The action
Polymorphism of Follicle-Stimulating Hormone Receptor Gene in PCOS

The general medical data including menstrual history, fertility, age, height, weight, and findings of the clinical examinations were recorded. Body mass index (BMI) was calculated as weight/height² (kg/m²) [19].

After a 12-hour overnight fast, venous blood samples were obtained for genetic study and for hormonal profile, glucose and insulin assays between 8-10 AM on 3th to the 5th day of menstrual cycles. For amenorrheic patients, blood samples were obtained after a progesterone-induced menstruation. Follicle stimulating hormone [FSH, reference value (RV): 2.5-10.2 mIU/ml], luteinizing hormone (LH, RV: 1.9-12.5 mIU/ml), estradiol (E2, RV: 19.5-144.2 mIU/ml), total testosterone (TT, RV: 14-76ng/dl), thyroid stimulating hormone (TSH, RV: 0.55-4.78 µU/ml), prolactine (PRL, RV: 2.8-29.2 ng/ml) were measured by Advia Centaur Xp Immunoassay System (Siemens, Gemany). TT values over the cut-off level of 76 ng/dl were defined as biochemical hyperandrogenism.

Plasma levels of fasting glucose (RV: 74-100 mg/dl), total cholesterol (CHO, RV: 0-200 mg/dl), triglycerides (TG; RV: 0-150 mg/dl), high-density lipoprotein (HDL, RV: 40-60 mg/dl), low-density lipoprotein (LDL; RV:0-130 mg/dl) levels were all detected by AU2700 Chemistry Analyzer (Beckman Coulter, USA). Fasting insulin (RV: 0-17 µU/ml) was measured by Immulite 2000 XPI Immunoassay System (Siemens, Gemany). Insulin resistance (IR) was identified by the HOMA-IR index obtained from the following calculation: HOMA-IR =fasting insulin (uIU/ml)xfasting glucose(mg/dl)/405, and the value of 2.5 was accepted to be the cut off point [20].

Each of the two groups (PCOS and control) were divided into three subgroups according to the genotypes of FSHR polymorphism: Asn-Asn (AA) as group 1, Asn-Ser(AS) as group 2, and Ser-Ser(SS) as group 3. All of the above mentioned parameters were compared between the PCOS and control group and also, among subgroups.

Genotyping

Genomic DNA was extracted from peripheral whole blood using MagPurix Blood DNA Extraction Kit by MagPurix 12 (Zinexts Life Science Corp., Taiwan). The genotyping procedure consisted of polymerase chain reaction (PCR) amplification and

PATIENTS AND METHODS

Subjects and clinical, hormonal and biochemical assessments

100 patients with PCOS and 100 controls were recruited from Erzincan University, Faculty of Medicine, Department of Obstetrics and Gynecology from January 2014 to May 2015. All subjects and the controls were from Eastern Turkey and were age- matched. PCOS was defined on the basis of the Rotterdam criteria [17]: 1. Oligo-ovulation and/or anovulation 2. Clinical and/or biochemical signs of hyperandrogenism, and 3. Polycystic morphology of the ovaries. Oligomenorrhea was defined as irregular menstrual cycles that are longer than 35 days, and amenorrhea was defined as absence of menstruation for more than 3 months without pregnancy. Clinical hirsutism was assessed using modified Ferriman – Gallwey score (mFG score) and defined to be present at a score of at least 8 [18]. Polycystic morphology of the ovaries was assessed by vaginal ultrasonography (Mindray DC-7T ultrasound machine, Shenzhen-Mindray Bio-Medical Electronics Co.Ltd., China) and defined as the presence of 12 or more follicles in one or both ovaries, and/or increased ovarian volume of >10 ml. All of the clinical measurements were performed by the same physician. Women who met at least two of these criteria were diagnosed as PCOS. Hyperprolactinemia, thyroid dysfunction, diabetes mellitus, Cushing syndrome, congenital adrenal hyperplasia, androgen secreting neoplasms were exclusion criteria. The control group included healthy fertile women with regular menstrual cycles who had no endocrine disorder related to PCOS. They had no clinical or biochemical signs of hyperandrogenism and polycystic ovaries. None of the subjects had been taking any medications that might affect hormone, lipid or carbohydrate metabolism for at least 3 months prior to starting the study. The study was approved by the Ethics Committee of the Erzincan University and written informed consent was obtained from each subject.

The general medical data including menstrual history, fertility, age, height, weight, and findings of the clinical examinations were recorded. Body mass index (BMI) was calculated as weight/height² (kg/m²) [19].

After a 12-hour overnight fast, venous blood samples were obtained for genetic study and for hormonal profile, glucose and insulin assays between 8-10 AM on 3th to the 5th day of menstrual cycles. For amenorrheic patients, blood samples were obtained after a progesterone-induced menstruation. Follicle stimulating hormone [FSH, reference value (RV): 2.5-10.2 mIU/ml], luteinizing hormone (LH, RV: 1.9-12.5 mIU/ml), estradiol (E2, RV: 19.5-144.2 mIU/ml), total testosterone (TT, RV: 14-76ng/dl), thyroid stimulating hormone (TSH, RV: 0.55-4.78 µU/ml), prolactine (PRL, RV: 2.8-29.2 ng/ml) were measured by Advia Centaur Xp Immunoassay System (Siemens, Gemany). TT values over the cut-off level of 76 ng/dl were defined as biochemical hyperandrogenism.

Plasma levels of fasting glucose (RV: 74-100 mg/dl), total cholesterol (CHO, RV: 0-200 mg/dl), triglycerides (TG; RV: 0-150 mg/dl), high-density lipoprotein (HDL, RV: 40-60 mg/dl), low-density lipoprotein (LDL; RV: 0-130 mg/dl) levels were all detected by AU2700 Chemistry Analyzer (Beckman Coulter, USA). Fasting insulin (RV: 0-17 µU/ml) was measured by Immulite 2000 XPI Immunoassay System (Siemens, Gemany). Insulin resistance (IR) was identified by the HOMA-IR index obtained from the following calculation: HOMA-IR =fasting insulin (uIU/ml)xfasting glucose(mg/dl)/405, and the value of 2.5 was accepted to be the cut off point [20].

Each of the two groups (PCOS and control) were divided into three subgroups according to the genotypes of FSHR polymorphism: Asn-Asn (AA) as group 1, Asn-Ser(AS) as group 2, and Ser-Ser(SS) as group 3. All of the above mentioned parameters were compared between the PCOS and control group and also, among subgroups.

Genotyping

Genomic DNA was extracted from peripheral whole blood using MagPurix Blood DNA Extraction Kit by MagPurix 12 (Zinexts Life Science Corp., Taiwan). The genotyping procedure consisted of polymerase chain reaction (PCR) amplification and

of FSH is mediated by FSH receptor (FSHR), a member of the G-protein coupled receptor family, which is only expressed by the granulosa cells of the ovary and Sertoli cells of the testis. The gene encoding for this receptor is located at chromosome 2p21 and consists of 10 exons, 9 introns [10]. Among many polymorphisms, found in the screening studies for mutations of the FSHR gene, the single nucleotide polymorphism (SNP) at position 680, occupied either by asparagine (ASN, N) or Serine (Ser, S) is of particular interest [11]. Since FSHR has an important role in signaling transmission of FSH, FSHR gene may be responsible for causing PCOS. On the basis of this approach, associations between FSHR gene polymorphisms and PCOS have been investigated. However, contradictory results are present in the literature. Gu et al revealed that the Asn680 Ser of FSHR was associated with PCOS in Korean women [9]. On the otherhand, Fu et al reported that the Asn680Ser polymorphism of FSHR was not a causative factor of PCOS in Chinese women [12]. All of these studies were conducted on different ethnic groups from different geographic regions. Moreover, some previous studies have showed the association of altered ovarian response with FSHR gene polymorphism at codon 680 and have suggested that this FSHR gene polymorphism can be used as a potential marker to predict poor ovarian response [13,14]. However, the reports from different populations such as the Netherlands and the UK have indicated no association between this polymorphism and poor ovarian response [15,16]. Thus, geography and race may be responsible for this discrepancy in the findings about the relation between FSHR-PCOS. In this cross-sectinal study, the frequency distribution of FSHR polymorphism at codon 680 was examined in a female population from the eastern provinces of Turkey and we also evaluated the association between this SNP and PCOS.
Polymorphism of Follicle-Stimulating Hormone Receptor Gene in PCOS

SNP detection of the c.2039G>A (p.Ser680Asn) mutation (rs6166) of FSHR gene using following pair of primers:

**Forward**
5’-TGTTAAACGACGGCCAAGTGAAGCTGCTGACTGTTGACTG-3’

**Reverse**
5’-CAGGAAAACGCTATGACCTGAGCAGCTGTCAGCTG-3’
by direct sequencing.

PCR amplification was carried out in a volume of 25 µl containing 100 ng sample DNA; Helix AmpTM Ready-2x-MultiPlex (Ver. 2.0) master mix was used; 25 nM of each primer; and 1 U of Taq polymerase were added to master mix (Nanohelix, South Korea). The amplification protocol conditions selected were as follows: Initial denaturation at 95 °C for 10 min, followed by 35 cycles of denaturation at 95 °C for 30 sec, annealing at 60 °C for 45 sec, extension at 72 °C for 45 sec and a final extension at 72 °C for 7 min. PCR products were purified as follows: 5 µl PCR products were treated with 2 µl of ExoSAP-IT enzyme (USB Affymetrix, USA) at 37 °C for 30 min and at 80 °C for 15 min. Sequence PCR (cycle sequencing) was done by reverse PCR primer (5 pmol) and BigDye® Terminator v3.1 Cycle Sequencing Kit (Lifetechnologies, USA). The PCR conditions were as follows: At 96 °C for 1 min, at 96 °C 10 sec, at 50 °C for 5 sec, at 60 °C for 4 min the cycle was repeated 25 times. Products of sequence PCR was purified (second purification) by spin colon (ZIR DNA Sequencing Clean-up Kit™, Zymo Research, USA). Sanger sequencing was performed by capillary electrophoresis after 5 min denaturation (3500 Genetic Analyzer, Lifetechnologies, USA). The obtained sequences were analyzed using by SeqScape® Software v3.0.

**Statistical Analysis**

The statistical analysis was performed using the Statistical Package for the Social Sciences version 22 (SPSS Inc., Chicago, IL, USA). Student t-test or Mann-Whitney U test was used to analyze the differences of continuous variables between the two groups. ANOVA and Kruskal-Wallis tests were used to analyze the differences among subgroups. Genotype and allele frequencies of Asn680Ser polymorphism in the PCOS patients. There were no significant differences between the PCOS group and the controls in age, FSH, E2, PRL, TSH and TT among the PCOS patients carrying 30% vs 32% for AA, 42% vs 34 for AS, 28% vs 34% for SS. No significant difference was found in genotype patterns between groups (χ²=0.744, P=0.689) (Table 2).

**RESULTS**

Some basic characteristics of the subjects were shown in Table 1. mFG score, plasma levels of LH, TT and fasting insulin, HOMA-IR were significantly higher in PCOS group than the controls (P<0.001, P<0.001, P<0.001, P=0.001, and P<0.004, respectively). There were no significant differences between the PCOS group and the controls in age, FSH, E2, PRL, TSH, fasting glucose, and lipid profile.

The difference between women with PCOS and controls in allelic frequencies for the polymorphism at codon Asn680 were not significant (P=0.777; OR=0.923). When the SNP at amino acid positions 680 was separately analyzed, the genotype patterns were distributed in PCOS patients versus controls as follows: 30% vs 32% for AA, 42% vs 34 for AS, 28% vs 34% for SS. No significant difference was found in genotype patterns between groups (χ²=0.744, P=0.689) (Table 2).

**Table 1. Baseline characteristics of the subjects**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Controls (n=100)</th>
<th>Cases (n=100)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year)</td>
<td>30.00 ± 3.49</td>
<td>30.94 ± 6.88</td>
<td>0.392</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.27 ± 4.60</td>
<td>30.00 ± 3.49</td>
<td>0.130</td>
</tr>
<tr>
<td>mFG score</td>
<td>10.40 ± 3.37</td>
<td>10.70 ± 6.15</td>
<td>0.392</td>
</tr>
<tr>
<td>FSH (mIU/mL)</td>
<td>5.47 ± 3.77</td>
<td>10.07 ± 6.15</td>
<td>0.005</td>
</tr>
<tr>
<td>LH (mIU/mL)</td>
<td>49.5 ± 13.3</td>
<td>44.98 ± 30.57</td>
<td>0.263</td>
</tr>
<tr>
<td>E2 (mIU/mL)</td>
<td>5.25 ± 1.56</td>
<td>4.80 ± 24.99</td>
<td>0.006</td>
</tr>
<tr>
<td>PRL (ng/mL)</td>
<td>14.32 ± 6.76</td>
<td>12.29 ± 5.55</td>
<td>0.176</td>
</tr>
<tr>
<td>TSH (mU/mL)</td>
<td>1.62 ± 0.72</td>
<td>1.62 ± 0.72</td>
<td>0.744</td>
</tr>
<tr>
<td>TT (ng/dL)</td>
<td>25.3 ± 14.3</td>
<td>25.3 ± 14.3</td>
<td>0.000</td>
</tr>
<tr>
<td>Fasting glucose (mg/dL)</td>
<td>87.68 ± 10.1</td>
<td>88.34 ± 11.14</td>
<td>0.004</td>
</tr>
<tr>
<td>Fasting insulin (µU/mL)</td>
<td>7.38 ± 3.93</td>
<td>12.86 ± 8.9</td>
<td>0.357</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>1.62 ± 0.72</td>
<td>2.74 ± 2.08</td>
<td>0.004</td>
</tr>
<tr>
<td>CHO (mg/dL)</td>
<td>171.3 ± 41.5</td>
<td>172.5 ± 41.1</td>
<td>0.357</td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td>114.7 ± 60.7</td>
<td>104.1 ± 52.0</td>
<td>0.892</td>
</tr>
<tr>
<td>HDL (mg/dL)</td>
<td>49.5 ± 13.3</td>
<td>52.3 ± 14.3</td>
<td>0.000</td>
</tr>
<tr>
<td>LDL (mg/dL)</td>
<td>102.9 ± 28.7</td>
<td>103.7 ± 29.5</td>
<td>0.000</td>
</tr>
</tbody>
</table>

Data are presented as Mean ± Standard deviation (SD) | BMI: Body mass index, mFG score: Modified Ferriman-Gallwey score, FSH: Follicle stimulating hormone, LH: Luteinizing hormone, E2: Estradiol, PRL: Prolactin, TSH: Thyroid stimulating hormone, TT: Total testosterone, HOMA-IR: Homeostasis model assessment, CHO: Cholesterol, TG: Triglycerides, HDL: High-density lipoprotein, LDL: Low-density lipoprotein

**Table 2. Genotype distribution and allele frequency of Asn680Ser polymorphism of FSHR**

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Cases (n=100)</th>
<th>Controls (n=100)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asn/Asn (AA)</td>
<td>30 (30%)</td>
<td>32 (32%)</td>
<td>0.689</td>
</tr>
<tr>
<td>Asn/Ser (AS)</td>
<td>42 (42%)</td>
<td>34 (34%)</td>
<td>0.347</td>
</tr>
<tr>
<td>Ser/Ser (SS)</td>
<td>28 (28%)</td>
<td>34 (34%)</td>
<td>0.347</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Allele frequency</th>
<th>Cases (n=100)</th>
<th>Controls (n=100)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asn (A)</td>
<td>98 (49%)</td>
<td>102 (51%)</td>
<td>0.777</td>
</tr>
<tr>
<td>Ser (S)</td>
<td>102 (51%)</td>
<td>98 (49%)</td>
<td></td>
</tr>
</tbody>
</table>

We further analyzed some clinical and endocrine parameters for Asn680Ser polymorphism in the PCOS patients. There were no statistical differences in BMI, mFG score, levels of fasting glucose and fasting insulin, HOMA-IR, AND also levels of FSH, LH, E2, PRL, TSH and TT among the PCOS patients carrying different genotypes of Asn680Ser polymorphism (Table 3).

www.jceionline.org
DISCUSSION

Investigations on the distribution of Asn680Ser polymorphism of FSHR gene produced conflicting results, regarding ethnic differences. Balkan et al., evaluated the SNP of the FSHR at codon 680 in men from Southeast Turkey and demonstrated that FSHR gene polymorphisms seemed not to have a direct effect on spermatogenesis, but were differently distributed, most likely due to the different genetic backgrounds in different populations [21]. The present study was first to report on the distribution of the SNP at codon 680 of the FSHR gene in Turkish women with PCOS from eastern provinces, comparing with the normal healthy controls. Our finding revealed that there were no differences in both allelic frequency and genotypes for Asn680Ser polymorphism in FSHR between the PCOS patients and controls. Kuijper et al. reported the distribution of SNPs at codon 608 of the FSHR gene in a large population of infertile patients from various ethnic backgrounds. However, they found that a significantly higher number of Asian women have an Asn608 Asn variant, compared with Caucasians and Mediterraneans. In the same study, for number of Asian women have an Asn608 Asn variant, compared with Caucasians and Mediterraneans. However, they found that a significantly higher number of Asian women have an Asn608 Asn variant compared to the Caucasian population [21]. The polymorphism at codon 608 was firstly reported by Aiitomaki in 1995 [25]. Since then, this SNP was investigated in patients with or without PCOS. However, the results are inconsistent. In a meta-analysis, it was suggested that there might be a significant association between Asn608Ser polymorphism and PCOS [26]. In accordance, Gu et al have reported that Asn608Ser may be associated with PCOS in Korean population [9]. Similarly, Sudo et al. reported a significantly higher prevalence of Asn608Ser polymorphism in Japanese PCOS women than in those who had regular ovulation [27]. On the other hand, while a study from the southeast China showed a significant association between PCOS and Asn608Ser polymorphism of FSHR in Han ethnic women [28], another study in the same population from North China revealed no association between PCOS and this SNP [29]. In addition, researchers did not find an association between FSHR gene polymorphism at codon 680 and PCOS in Thai women [30]. Also, no association was found between PCOS and Asn680Ser polymorphism in a Caucasian population from Netherlands [8]. This finding was supported by the study conducted on Turkish adolescent girls with PCOS [31]. According to our results, PCOS seems not to be associated with Asn680Ser polymorphism in women from eastern Turkey. Given the data from the literature presented, studies conducted in different ethnic populations and/or in different geographic regions may lead to discrepant results of the interrelationship between FSHR polymorphisms and PCOS.

FSH is essential for normal reproductive functions. Due to the important roles of FSH on follicular growth and steroidogenesis in females, mutations in the FSHR gene could affect reproductive ability. Based on this data, genetic variations in the FSHR gene have been extensively studied in association with ovulatory dysfunction, especially to clarify the etiopathogenesis of PCOS. The polymorphism at codon 680 was firstly reported by Aitiotamaki in 1995 [25]. Since then, this SNP was investigated in patients with or without PCOS. However, the results are inconsistent. In a meta-analysis, it was suggested that there might be a significant association between Asn680Ser polymorphism and PCOS [26]. In accordance, Gu et al have reported that Asn680Ser may be associated with PCOS in Korean population [9]. Similarly, Sudo et al. reported a significantly higher prevalence of Asn680Ser polymorphism in Japanese PCOS women than in those who had regular ovulation [27]. On the other hand, while a study from the southeast China showed a significant association between PCOS and Asn608Ser polymorphism of FSHR in Han ethnic women [28], another study in the same population from North China revealed no association between PCOS and this SNP [29]. In addition, researchers did not find an association between FSHR gene polymorphism at codon 680 and PCOS in Thai women [30]. Also, no association was found between PCOS and Asn680Ser polymorphism in a Caucasian population from Netherlands [8]. This finding was supported by the study conducted on Turkish adolescent girls with PCOS [31]. According to our results, PCOS seems not to be associated with Asn680Ser polymorphism in women from eastern Turkey. Given the data from the literature presented, studies conducted in different ethnic populations and/or in different geographic regions may lead to discrepant results of the interrelationship between FSHR polymorphisms and PCOS.
Patients with PCOS are susceptible to infertility, obesity and insulin resistance [32]. Based on this data, we investigated whether there was a correlation between FSHR polymorphism at codon 680 and BMI in PCOS patients with respect to the genotypes. We observed no significant differences in BMI among different genotypes of Asn680Ser polymorphism of FSHR in PCOS. Similarly, Wu et al and Singhase et al have reported no correlation between BMI and FSHR polymorphism in PCOS patients [29,30].

Most women with PCOS, both obese and lean, have a degree of insulin resistance. Recently, it has been reported that abnormal serine phosphorylation of insulin receptor (IR) may lead to a defect in insulin action and also, polymorphic alleles of insulin receptor substrate 1 and 2 (IRS-1 and IRS-2) have a functional impact on the insulin-resistant component of PCOS [3]. To our knowledge, our study was the first to investigate the association among IR, Ser680Asn polymorphism of FSHR and PCOS in literature. Our findings have indicated no association between IR and this SNP in PCOS.

We also assessed a panel of PCOS-associated endocrine hormones with respect to the genotypes of Asn680Ser polymorphism in PCOS. Our data showed no significant differences for the levels of FSH, LH, E2, PRL, TSH, and TT among AA, AS and SS variants in PCOS patients. There are similar studies in literature, supporting our results [22,31]. In contrast, some studies have suggested that women with Ser680Ser have a higher ovarian threshold for FSH, resulting in higher serum FSH concentrations [23,33]. Additionally, the Asn680Ser polymorphism of FSHR was reported to be related to the levels of FSH and PRL while other PCOS–associated endocrine hormones were not [29]. In another study by Fu et al, this SNP was found to be associated with high levels of FSH and low E2 levels [12].

In conclusion, our results indicate that there is no association between Asn680Ser polymorphism of FSHR and PCOS in Turkish women from eastern provinces of Turkey. In addition, this SNP seems not to be associated with BMI, IR and PCOS-associated endocrine hormones. Based on the evidence, ethnicity and geographical region may influence the polymorphism pattern. Therefore, further study on a large sample of Turkish population is needed to explore the role of FSHR polymorphisms in PCOS.

Conflict of interest: All of the authors declared no conflicts of interest related to this study.

Financial Disclosure: No financial support was received.

REFERENCES


